Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod in Early-Stage Huntington Disease
NCT03980938Phase 2Terminated
- Sponsor
- CervoMed
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of neflamapimod in Huntington disease (HD), sponsored by CervoMed. Started Jul 2019; status: terminated.
02
Drugs
neflamapimod
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT03980938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980938.